<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Some interactions between carbamazepine and other antiseizure medications*</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Some interactions between carbamazepine and other antiseizure medications*</h1>
<div class="graphic"><div class="figure"><div class="ttl">Some interactions between carbamazepine and other antiseizure medications*</div><div class="cntnt"><table cellspacing="0"><colgroup width="20%"></colgroup><colgroup span="2" width="40%"></colgroup> <tbody> <tr> <td class="subtitle1">Interacting drugs</td> <td class="subtitle1">Effects (probable mechanism)</td> <td class="subtitle1">Management</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Carbamazepine, with:</td> </tr> <tr class="divider_top"> <td class="indent1 divider_bottom" rowspan="2">Brivaracetam</td> <td>Possible carbamazepine toxicity (decreased metabolism of active epoxide metabolite<sup>¶</sup>)</td> <td>Monitor clinical status; reduction of carbamazepine dose may be needed</td> </tr> <tr class="divider_bottom"> <td>Decreased brivaracetam effect (increased metabolism by CYP2C19)</td> <td>Monitor clinical status; brivaracetam dose may need to be adjusted</td> </tr> <tr class="divider_bottom"> <td class="indent1">Clonazepam</td> <td>Decreased clonazepam effect (increased metabolism by CYP3A4)</td> <td>Monitor clinical status</td> </tr> <tr> <td class="indent1 divider_bottom" rowspan="2">Felbamate</td> <td>Possible carbamazepine toxicity (increased concentration of active epoxide metabolite<sup>¶</sup>)</td> <td>Monitor clinical status; felbamate and carbamazepine dose may need to be adjusted</td> </tr> <tr class="divider_bottom"> <td>Decreased felbamate effect (increased metabolism by CYP3A4)</td> <td>A reduction in carbamazepine dose is recommended when felbamate is added to carbamazepine therapy. Specific dose adjustment recommendations are provided in the Lexicomp monograph.</td> </tr> <tr> <td class="indent1 divider_bottom" rowspan="2">Lamotrigine</td> <td>Carbamazepine toxicity (increased concentration of active epoxide metabolite<sup>¶</sup>)</td> <td>Monitor clinical status; serum carbamazepine measurements alone may not predict toxicity</td> </tr> <tr class="divider_bottom"> <td>Decreased lamotrigine effect (increased metabolism; glucuronidation)</td> <td>Monitor clinical status and lamotrigine concentrations; lamotrigine dose may need to be increased. Specific lamotrigine dose adjustment recommendations are provided in the Lexicomp monograph.</td> </tr> <tr class="divider_bottom"> <td class="indent1" rowspan="2">Levetiracetam</td> <td>Possible increased risk of carbamazepine toxicity (mechanism not established)</td> <td>Monitor for clinical evidence of carbamazepine toxicity</td> </tr> <tr class="divider_bottom"> <td>Possible decreased levetiracetam concentrations (increased metabolism)</td> <td>Monitor clinical effect</td> </tr> <tr class="divider_bottom"> <td class="indent1">Perampanel</td> <td>Decreased perampanel effect (increased metabolism by CYP3A4)</td> <td>Monitor clinical status; perampanel dosage may need to be adjusted</td> </tr> <tr> <td class="indent1 divider_bottom" rowspan="2">Phenytoin</td> <td>Decreased carbamazepine effect (increased metabolism)</td> <td class="divider_bottom" rowspan="2">Monitor clinical status and carbamazepine and phenytoin concentrations</td> </tr> <tr class="divider_bottom"> <td>Altered phenytoin effect may include decreased or increased phenytoin levels (mechanism not established)</td> </tr> <tr class="divider_bottom"> <td class="indent1">Tiagabine</td> <td>Decreased tiagabine effect (increased metabolism by CYP3A4)</td> <td>Monitor clinical status</td> </tr> <tr class="divider_bottom"> <td class="indent1">Topiramate</td> <td>Possible decreased topiramate effect (increased metabolism); possible additive CNS side effects (mechanism not established)</td> <td>Monitor clinical status; may need higher doses of topiramate</td> </tr> <tr> <td class="indent1 divider_bottom" rowspan="2">Valproate</td> <td>Decreased valproate effect and possible increased toxicity (increased metabolism by CYP 2C9, 2C19, glucuronidation, and formation of toxic metabolite)</td> <td>Monitor clinical status and valproate concentrations</td> </tr> <tr class="divider_bottom"> <td>Carbamazepine toxicity (increased concentration of active epoxide metabolite<sup>¶</sup> and displacement from binding sites)</td> <td>Monitor clinical status, carbamazepine, and carbamazepine epoxide concentrations; carbamazepine dose may need to be adjusted</td> </tr> <tr> <td class="indent1">Zonisamide</td> <td>Decreased zonisamide effect (increased metabolism by CYP3A4)</td> <td>Monitor zonisamide concentrations and clinical status; zonisamide dosage may need to be adjusted</td> </tr> </tbody></table></div><div class="graphic_lgnd">Carbamazepine is a strong inducer of multiple hepatic enzymes; it can reduce serum concentrations of other drugs, including antiseizure medications. Carbamazepine is metabolized by CYP3A4 and induces its own metabolism; serum concentrations of carbamazepine fall after first few weeks of initial therapy. Other drugs that are inducers or inhibitors of CYP3A4 can alter serum concentrations of carbamazepine and epoxide active metabolite. A list of CYP3A4 inhibitors and inducers is available in a separate table in UpToDate.</div><div class="graphic_footnotes">CYP: cytochrome P450.<br/>
	
	* <strong>Not all potential interactions are listed.</strong> Additional interactions of antiseizure medications and management suggestions may be determined by using the drug interactions program included within UpToDate.<br/>
	
	¶ Routine carbamazepine serum measurements do not assess for accumulation of the active carbamazepine-epoxide metabolite, but this metabolite can be measured as a separate test; refer to accompanying text.</div><div class="graphic_reference">Data from: Lexicomp Online. Copyright © 1978-2024 Lexicomp, Inc. All Rights Reserved.</div><div id="graphicVersion">Graphic 80801 Version 20.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
